How We Mark Time and How Time Marks Us
Dr. Gotlib discusses the road to approval of midostaurin for the treatment of advanced systemic mastocytosis.
Abrogating Early Treatment Resistance in Early T-cell Precursor Acute Lymphoblastic Leukemia
Dr. Raetz looks at a study that shows response-based therapy in both children and adults with ETP-ALL is effective.
A concise review of a topic that illustrates the relationship of basic research to clinical hematology
Dr. Abdel-Wahab provides an overview of histiocytoses or histiocytic neoplasms, some of the most challenging hematologic disorders to diagnose and categorize.
Drs. Sojitra, Arber, and George cover the 2017 joint guidelines from ASH and the College of American Pathologists on testing for the initial workup of acute leukemia.
Dr. Hoggatt discusses stem cell transplantation and looks at new, targeted conditioning approaches that have recently emerged, where the potential patient pool could be remarkably expanded with the advent of new gene therapy and editing strategies.
Dr. George and Dr. Czuchlewski cover the World Health Organization's 2016 updates to the classification of myeloid neoplasms.
Dr. Garcia highlights clinical recommendations from the ACCP's evidence-based guidelines for the treatment of venous thromboembolism (VTE) that are most relevant to hematologists.
Dr. Yang and Dr. Press evaluate the clinical utility of next-generation DNA sequencing (NGS) methods to profile the multiple actionable driver genes in patients with known and/or suspected myeloid malignancies.
Drs. Yao, Cardó-Vila, Ahmadian, Ebaid, Arap, and Pasqualini discuss the existence of tumor-specific molecular zip codes that can be used to design drugs to treat leukemia, lymphoma, and solid tumors.
Drs. Oh and Fisher discuss the application of mass cytometry to analyze disease evolution in hematologic malignancies.
Dr. Raje and Dr. Santo discuss new insights into MM-related bone biology and potential novel therapeutic approaches for treating bone disease.
Drs. Falet, Grozovsky, and Hoffmeister look at desialylated platelets to understand the steady state of hepatic TPO regulation and the mechanisms of thrombocytopenia observed in patients with MPNs treated with JAK1/2 inhibitors.
July-August 2017Volume 14, Issue 4
A new Compendium providing updated clinical information to "Ask the Hematologist" articles published in The Hematologist from 2010 to 2015 is now available.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology